Research programme: anti-viral small molecule therapeutics - Oncotelic Therapeutics
Latest Information Update: 28 Apr 2024
At a glance
- Originator Mateon Therapeutics
 - Developer Oncotelic Therapeutics
 - Class Antivirals; Small molecules
 - Mechanism of Action Cathepsin K modulators; Cathepsin L modulators
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 - Available For Licensing Yes - COVID 2019 infections; Viral infections
 
Highest Development Phases
- No development reported COVID 2019 infections; Viral infections
 
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in COVID-2019-infections in USA
 - 28 Apr 2024 No recent reports of development identified for research development in Viral-infections in USA
 - 02 Mar 2020 Research programme: anti-viral small molecule therapeutics - Mateon Therapeutics is available for licensing as of 02 Mar 2020. https://www.oncotelic.com/